Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, represents approximately 15%–20% of all BC cases (3, 4). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.